1,3,4,4a,5,6,7,8a-Octahydro-1,7-naphthyridine-2,8-dione

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 1,3,4,4a,5,6,7,8a-Octahydro-1,7-naphthyridine-2,8-dione
• 化学式: C₈H₁₂N₂O₂
• 分子量: 168.19
• InChiKey: IRGJBHGPBKJIDG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  12
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  58.2
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• Diazabicyclic central nervous system active agents
  申请人：——

  公开号：US20020019388A1

  公开（公告）日：2002-02-14

  Compounds of formula I 1 pharmaceutical compositions of these compounds, and use of said compositions to control synaptic transmission in mammals.

  式I1的化合物，这些化合物的药物组合物，以及利用这些组合物来控制哺乳动物的突触传递。
• [EN] HTT MODULATORS FOR TREATING HUNTINGTON'S DISEASE<br/>[FR] MODULATEURS HTT POUR LE TRAITEMENT DE LA MALADIE DE HUNTINGTON
  申请人：CHDI FOUNDATION INC

  公开号：WO2021231571A1

  公开（公告）日：2021-11-18

  Provided herein are certain compounds useful as HTT modulators. Such compound are useful in the treatment of Huntington's disease.

  以下提供了一些作为HTT调节剂有用的化合物。这些化合物在亨廷顿病的治疗中很有用。
• Compounds capable of activating cholinergic receptors
  申请人：——

  公开号：US20030125345A1

  公开（公告）日：2003-07-03

  The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.

  本发明通常涉及烟碱化合物，以芳基取代的烯烃化合物形式存在，以及它们的前药、N-氧化物、代谢物和药用可接受盐形式。还公开了通过给予这些化合物、前药、N-氧化物和/或药用可接受盐来调节神经递质释放的方法。
• Novel dicationic imidazo[1,2-a]pyridines and 5,6,7,8,-tetrahydro-imidazo[1,2,-a]pyridines as antiprotozoal agents
  申请人：Boykin W. David

  公开号：US20050282853A1

  公开（公告）日：2005-12-22

  A method for treating a microbial infection, including an infection from a protozoan pathogen, such as Trypanosoma brucei rhodesiense and Plasmodium falciparum , in a subject in need thereof by administering to the subject an effective amount of a dicationic imidazopyridine compound or a dicationic tetrahydro-imidazopyridine compound. Processes for synthesizing dicationic imidazopyridines and dicationic tetrahydro-imidazopyridines and the novel dicationic imidazopyridine and dicationic tetrahydro-imidazopyridine compounds themselves.

  一种治疗微生物感染的方法，包括治疗来自原虫病原体（如Trypanosoma brucei rhodesiense和Plasmodium falciparum）的感染，通过向需要的对象施用有效量的二阳离子咪唑吡啶化合物或二阳离子四氢咪唑吡啶化合物。合成二阳离子咪唑吡啶和二阳离子四氢咪唑吡啶的方法，以及新型的二阳离子咪唑吡啶和二阳离子四氢咪唑吡啶化合物本身。
• [EN] COMPOUNDS CAPABLE OF ACTIVATING CHOLINERGIC RECEPTORS<br/>[FR] COMPOSES POUVANT ACTIVER DES RECEPTEURS CHOLINERGIQUES
  申请人：TARGACEPT INC

  公开号：WO2004031151A1

  公开（公告）日：2004-04-15

  The present invention generally relates to nicotinic compounds, in the form of aryl substituted olefinic compounds, as well as pro-drug, N-oxide, metabolite and pharmaceutically acceptable salt forms thereof. Methods of modulating neurotransmitter release via administration of the compounds, pro-drugs, N-oxides and/or pharmaceutically acceptable salts are also disclosed.

  本发明一般涉及尼古丁化合物，以芳基取代的烯烃化合物的形式存在，以及它们的前药、N-氧化物、代谢物和药学上可接受的盐形式。本发明还揭示了通过给予化合物、前药、N-氧化物和/或药学上可接受的盐来调节神经递质释放的方法。